291 related articles for article (PubMed ID: 24666649)
1. Reversal of new, factor-specific oral anticoagulants by rFVIIa, prothrombin complex concentrate and activated prothrombin complex concentrate: a review of animal and human studies.
Lee FM; Chan AK; Lau KK; Chan HH
Thromb Res; 2014 May; 133(5):705-13. PubMed ID: 24666649
[TBL] [Abstract][Full Text] [Related]
2. Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitro.
Perzborn E; Heitmeier S; Laux V; Buchmüller A
Thromb Res; 2014 Apr; 133(4):671-81. PubMed ID: 24529498
[TBL] [Abstract][Full Text] [Related]
3. More efficient reversal of dabigatran inhibition of coagulation by activated prothrombin complex concentrate or recombinant factor VIIa than by four-factor prothrombin complex concentrate.
Lindahl TL; Wallstedt M; Gustafsson KM; Persson E; Hillarp A
Thromb Res; 2015 Mar; 135(3):544-7. PubMed ID: 25596769
[TBL] [Abstract][Full Text] [Related]
4. Reversal of rivaroxaban anticoagulation by haemostatic agents in rats and primates.
Perzborn E; Gruber A; Tinel H; Marzec UM; Buetehorn U; Buchmueller A; Heitmeier S; Laux V
Thromb Haemost; 2013 Jul; 110(1):162-72. PubMed ID: 23636219
[TBL] [Abstract][Full Text] [Related]
5. In vitro reversal of supratherapeutic rivaroxaban levels with coagulation factor concentrates.
Körber MK; Langer E; Kaufner L; Sander M; Von Heymann C
Blood Transfus; 2016 Sep; 14(5):481-6. PubMed ID: 27177413
[TBL] [Abstract][Full Text] [Related]
6. The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII against anticoagulation of Xa inhibitor.
Schultz NH; Tran HTT; Bjørnsen S; Henriksson CE; Sandset PM; Holme PA
Thromb J; 2017; 15():6. PubMed ID: 28239301
[TBL] [Abstract][Full Text] [Related]
7. Prothrombin complex concentrates and a specific antidote to dabigatran are effective ex-vivo in reversing the effects of dabigatran in an anticoagulation/liver trauma experimental model.
Grottke O; van Ryn J; Spronk HM; Rossaint R
Crit Care; 2014 Feb; 18(1):R27. PubMed ID: 24499559
[TBL] [Abstract][Full Text] [Related]
8. Multimodal assessment of non-specific hemostatic agents for apixaban reversal.
Martin AC; Gouin-Thibault I; Siguret V; Mordohay A; Samama CM; Gaussem P; Le Bonniec B; Godier A
J Thromb Haemost; 2015 Mar; 13(3):426-36. PubMed ID: 25630710
[TBL] [Abstract][Full Text] [Related]
9. Prothrombin complex concentrate versus recombinant factor VIIa for reversal of coumarin anticoagulation.
Dickneite G
Thromb Res; 2007; 119(5):643-51. PubMed ID: 16842841
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of recombinant activated factor VII, prothrombin complex concentrate, and fibrinogen concentrate to reverse apixaban in a rabbit model of bleeding and thrombosis.
Martin AC; Le Bonniec B; Fischer AM; Marchand-Leroux C; Gaussem P; Samama CM; Godier A
Int J Cardiol; 2013 Oct; 168(4):4228-33. PubMed ID: 23928345
[TBL] [Abstract][Full Text] [Related]
11. Dabigatran and its reversal with recombinant factor VIIa and prothrombin complex concentrate: a Sonoclot in vitro study.
Sølbeck S; Nilsson CU; Engström M; Ostrowski SR; Johansson PI
Scand J Clin Lab Invest; 2014 Oct; 74(7):591-8. PubMed ID: 24909158
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the prothrombotic potential of four-factor prothrombin complex concentrate (4F-PCC) in animal models.
Ghosh S; Krege W; Doerr B; Mischnik M; Pragst I; Dickneite G; Herzog E
PLoS One; 2021; 16(10):e0258192. PubMed ID: 34614035
[TBL] [Abstract][Full Text] [Related]
13. Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents.
Fukuda T; Honda Y; Kamisato C; Morishima Y; Shibano T
Thromb Haemost; 2012 Feb; 107(2):253-9. PubMed ID: 22186946
[TBL] [Abstract][Full Text] [Related]
14. Reversal of the inhibitory effect of fondaparinux on thrombin generation by rFVIIa, aPCC and PCC.
Desmurs-Clavel H; Huchon C; Chatard B; Negrier C; Dargaud Y
Thromb Res; 2009 Mar; 123(5):796-8. PubMed ID: 18771795
[TBL] [Abstract][Full Text] [Related]
15. A direct thrombin inhibitor studied by dynamic whole blood clot formation. Haemostatic response to ex-vivo addition of recombinant factor VIIa or activated prothrombin complex concentrate.
Sørensen B; Ingerslev J
Thromb Haemost; 2006 Oct; 96(4):446-53. PubMed ID: 17003921
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model.
Godier A; Miclot A; Le Bonniec B; Durand M; Fischer AM; Emmerich J; Marchand-Leroux C; Lecompte T; Samama CM
Anesthesiology; 2012 Jan; 116(1):94-102. PubMed ID: 22042412
[TBL] [Abstract][Full Text] [Related]
17. Reversal of apixaban induced alterations in haemostasis by different coagulation factor concentrates in patients after hip or knee replacement surgery.
Schmidt K; Krüger K; Langer E; Schmutzler M; Johnen E; Wernecke KD; von Heymann C; Körber MK
Blood Transfus; 2019 Mar; 17(2):157-162. PubMed ID: 29757137
[TBL] [Abstract][Full Text] [Related]
18. The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII in apixaban-treated patients in vitro.
Schultz NH; Tran HTT; Bjørnsen S; Henriksson CE; Sandset PM; Holme PA
Res Pract Thromb Haemost; 2017 Jul; 1(1):49-56. PubMed ID: 30046673
[TBL] [Abstract][Full Text] [Related]
19. Emergency reversal of pentasaccharide anticoagulants: a systematic review of the literature.
Elmer J; Wittels KA
Transfus Med; 2012 Apr; 22(2):108-15. PubMed ID: 22171588
[TBL] [Abstract][Full Text] [Related]
20. Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor.
Elg M; Carlsson S; Gustafsson D
Thromb Res; 2001 Feb; 101(3):145-57. PubMed ID: 11228338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
